Harriet E. Feilotter

机构：University Health Network, University of Toronto, Queen's University, Toronto General Hospital, Princess Margaret Cancer Centre · ORCID：0000-0002-1388-2183

发表论文 174 篇 · 总被引 4970 次 · h-index 34

代表论文

• Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial (2024 · Clinical Cancer Research · 被引 20)
• Guidance for securing approvals for new biomarkers: from discovery to clinical implementation (2024 · Critical Reviews in Clinical Laboratory Sciences · 被引 10)
• Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies (2023 · JTO Clinical and Research Reports · 被引 6)
• Kinetic Profiling of RAS Mutations With Circulating Tumor DNA in the Canadian Cancer Trials Group CO.26 Trial Suggests the Loss of RAS Mutations in Neo-RAS-Wildtype Metastatic Colorectal Cancer Is Transient (2024 · JCO Precision Oncology · 被引 5)
• Future Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective (2023 · Current Oncology · 被引 5)
• The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative (2025 · Cancer Cell · 被引 4)